(Q46429821)

22 December 2017

title

A promising new treatment for Alzheimer's disease? (English)

1 reference

22 December 2017

0 references

John T O'Brien

1

1 reference

22 December 2017

publication date

1 September 2008

1 reference

22 December 2017

published in

Lancet Neurology

1 reference

22 December 2017

volume

7

1 reference

22 December 2017

issue

9

1 reference

22 December 2017

page(s)

768-769

1 reference

22 December 2017

Global prevalence of dementia: a Delphi consensus study

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

Integrated multidisciplinary diagnostic approach for dementia care: randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

NICE and anti-dementia drugs: a triumph of health economics over clinical wisdom?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2808%2970177-7

7 January 2021

10.1016/S1474-4422(08)70177-7

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017